Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
Zacks Investment Research on MSN3h
AMGN's Eczema Drug Meets Goal in Two Late-Stage StudiesAmgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
In a report released on March 7, Stephen Barker from Jefferies maintained a Buy rating on Kyowa Kirin Co (KYKOF – Research Report), with a ...
Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...
Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...
PRINCETON, N.J., Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting ...
We view Kyowa Kirin and Coca-Cola Beverages Northeast as two segments that have a more certain profit outlook over the next few years. However, the bumpy path associated with Kyowa Hakko may raise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback